Georgia Bio Responds to Biden Administration’s Federal TRIPS Waiver

“On behalf of Georgia Bio and the biotechnology industry in Georgia, we have grave concerns about the Biden administration’s decision to waive the intellectual property patent for American vaccine technology. Countless hours went into safely researching, developing, and producing these life-saving vaccines, and this decision could ultimately undermine global supply chains and ongoing vaccination efforts worldwide – especially for healthcare systems in low-and middle-income countries. We join our friends at Biotechnology Innovation Organization (BIO) in asking for a more thoughtful, patient-centered approach as we navigate this new challenge in the fight against COVID-19 and subsequent global health crises.” – Maria Thacker-Goethe, President & CEO, Georgia Bio

Read the full Biotechnology Innovation Organization (BIO) statement here.